Amgen (AMGN) Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Does the media prefer GILD or AMGN?

In the previous week, Gilead Sciences had 21 more articles in the media than Amgen. MarketBeat recorded 71 mentions for Gilead Sciences and 50 mentions for Amgen. Amgen's average media sentiment score of 1.23 beat Gilead Sciences' score of 1.02 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	44 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	39 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, GILD or AMGN?

Gilead Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Is GILD or AMGN more profitable?

Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	21.86%	50.99%	17.24%
Amgen	18.96%	174.71%	13.12%

Do analysts prefer GILD or AMGN?

Gilead Sciences currently has a consensus price target of $115.39, indicating a potential upside of 0.54%. Amgen has a consensus price target of $303.76, indicating a potential upside of 3.42%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	2.88
Amgen	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.33

Do institutionals & insiders have more ownership in GILD or AMGN?

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, GILD or AMGN?

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$28.75B	4.95	$480M	$5.02	22.86
Amgen	$33.42B	4.73	$4.09B	$12.23	24.02

Is GILD or AMGN a better dividend stock?

Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.